The use, misuse and abuse of dabigatran

Medical Journal of Australia

Volumn 198, Issue 7, 2013, Pages 356-357

  Attia, John R ^a   Pearce, Robert ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AUSTRALIA; BLEEDING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG MISUSE; DRUG POTENTIATION; DRUG STABILITY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GERIATRICS; GLOMERULUS FILTRATION RATE; HEALTH CARE DELIVERY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW RISK POPULATION; NEUROLOGIC DISEASE; NOTE; PATENT; PRACTICE GUIDELINE; PRESCRIPTION; URINARY EXCRETION;

ADVERTISING AS TOPIC; ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; AUSTRALIA; BENZIMIDAZOLES; BETA-ALANINE; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RESEARCH DESIGN; SELECTION BIAS; STROKE; WARFARIN;

EID: 84876245670     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10729     Document Type: Note

References (14)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
3. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
4. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 2001; 37: 569-578.
5. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
6. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
7. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
8. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011; 343: d6333.
9. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke propylaxis in atrial fibrillation. Circulation 2011; 123: 2562-2570.
10. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
11. Department of Health and Ageing. Public summary documents by product. Dabigatran etexilate, capsules, 110mg and 150mg (as mesilate), Pradaxa®-March 2011. http:// www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-dabigatranmarch11 (accessed Nov 2012).
12. O'Brien M. GPs reveal big issues for 2012. Medical Observer 2011; 19 Dec. http:// www.medicalobserver.com.au/news/gps-reveal-big-issues-for-2012 (accessed Oct 2012).
13. Medicines Australia. Code of conduct-current edition. http:// medicinesaustralia.com.au/code-of-conduct/code-of-conduct-current-edition/ (accessed Nov 2012).
14. Dunlevy S. Pharma giant puts heat on Gillard after subsidy refusal. The Australian 2011; 3 Nov. http://www.theaustralian.com.au/national-affairs/health/pharma-giant-putsheat-on-gillard-after-subsidy-refusal/story-fn59nokw-1226184055515 (accessed Oct 2012).